BioCentury | May 4, 2018
Targets & Mechanisms

Solid hopes for T cell bispecifics

...Roche (SIX:ROG; OTCQX:RHHBY), AMG 211 from Amgen, ERY974 from Chugai Pharmaceutical Co. Ltd. (Tokyo:4519) and APVO414...
...malignancies Phase I Primary completion July 2019 Aptevo Therapeutics Inc. (NASDAQ:APVO)/ MorphoSys AG (Xetra:MOR; NASDAQ:MOR) APVO414...
BioCentury | Sep 8, 2017
Company News

Aptevo regains rights to MOR209/ES414 from MorphoSys

...deal with MorphoSys AG (Xetra:MOR; Pink:MPSYY) granting the German company worldwide rights to APVO414 (formerly MOR209/ES414...
...Pink:MPSYY), Martinsried, Germany Business: Cancer Shannon Lehnbeuter MOR209/ES414 Aptevo Therapeutics Inc. Emergent BioSolutions Inc. MorphoSys AG Prostate-specific membrane antigen (PSMA) (FOLH1) (GCPII) APVO414...
BioCentury | Aug 8, 2016
Company News

Emergent BioSolutions, Aptevo deal

...pipeline includes Emergent’s ADAPTIR platform, including bispecific therapeutics based on redirected T cell cytotoxicity; and MOR209/ES414...
...were $7.9 million. In 2014, Emergent and MorphoSys AG (Xetra:MOR, Martinsried, Germany) partnered to develop ES414...
BioCentury | Sep 14, 2015
Company News

Emergent BioSolutions cancer, hematology news

...spinout will gain Emergent’s ADAPTIR platform, including bispecific therapeutics based on redirected T cell cytotoxicity; MOR209/ES414...
BioCentury | Mar 23, 2015
Clinical News

MOR209/ES414: Phase I started

...BioSolutions Inc . (NYSE:EBS), Rockville, Md. MorphoSys AG (Xetra:MOR; Pink:MPSYF), Martinsried, Germany Product: MOR209/ES414 (formerly ES414...
...data (08/2016) MorphoSys and Emergent began an open-label, international Phase I trial to evaluate IV MOR209/ES414...
...other week thereafter in up to 130 patients. A dose-escalation part will evaluate 0.2-300 ug/kg MOR209/ES414...
BioCentury | Nov 10, 2014
Finance

Convert resurgence

...an upfront payment from MorphoSys AG (Xetra:MOR; Pink:MPSYF) under an August deal to jointly develop MOR209/ES414...
BioCentury | Sep 22, 2014
Product Development

Glenmark's new cancer BEAT

...binding domain, an effector domain based on immunoglobulin Fc regions, and a C-terminal binding domain MOR209/ES414...
BioCentury | Sep 1, 2014
Finance

Highlights of weekly biotech stock moves

...of Aug. 18 after partnering with Emergent BioSolutions Inc. (NYSE:EBS) to develop and commercialize Emergent's ES414...
BioCentury | Sep 1, 2014
Company News

Emergent BioSolutions, MorphoSys deal

...MorphoSys partnered with Emergent to develop and commercialize ES414 . Emergent developed the bispecific ADAPTIR antibody...
...PSMA ; FOLH1 ; GCPII ) and CD3. The compound -- to be renamed MOR209/ES414...
BioCentury | Aug 20, 2014
Company News

Emergent, MorphoSys to co-develop MOR209/ES414

...MorphoSys AG (Xetra:MOR; Pink:MPSYF) partnered with Emergent BioSolutions Inc. (NYSE:EBS) to develop and commercialize ES414...
...PSMA ; FOLH1 ; GCPII ) and CD3. The compound -- to be renamed MOR209/ES414...
Items per page:
1 - 10 of 11